ATB-320 / Autotelic - LARVOL DELTA

ATB-320-001A: Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Autotelicbio | Trial completion date: Jun 2028 ➔ Dec 2028 | Initiation date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2028 ➔ Dec 2028

Trial completion date • Trial initiation date • Trial primary completion date • Solid Tumor

Autotelic Bio, ATB-320 Australian Phase 1 Clinical Trial Approved… KOSDAQ Listing Begins in Full Swing [Google translation] (HIT News) - "Autotelic Bio...announced on the 21st that it received approval for the Phase 1 clinical trial plan (IND) for the anticancer ASO (antisense oligonucleotide) new drug candidate 'ATB-320' from the Australian Bellberry Human Research Ethics Committee (HREC). In addition, it signed a contract with Kiwoom Securities as the lead manager for the KOSDAQ listing and began full-scale procedures with the goal of listing next year....The trial is designed as a multi-center, open-label method to evaluate safety and tolerability for patients with advanced or metastatic solid tumors."

Commercial • New P1 trial • Solid Tumor

ATB-320-001A: Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Autotelicbio

New P1 trial • Solid Tumor